Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.
The oxidative polymorphism of debrisoquine (DBQ) has been determined in 89 patients with colo-rectal cancer and in 556 normal control subjects. Four patients and 34 controls, with a metabolic ratio greater than 12.6, were classified as poor metabolisers of DBQ (n.s.). No difference was found in the distribution of the frequencies of the MR of DBQ between patients and controls. It is concluded that polymorphic oxidation of DBQ is not related to the risk of developing colo-rectal cancer in human beings.
Ladero
J M
JM
Department of Medicine, Universidad Complutense, Madrid, Spain.
Benítez
J
J
González
J F
JF
Vargas
E
E
Díaz-Rubio
M
M
D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000209:etiology / Q000378:metabolism*; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic
D003647:Debrisoquin